Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bridging the computational-experimental gap: leveraging large language model to prioritize Alzheimer's therapeutics based on comparison of learning models.

npj health systems·2026

Same author

Leveraging multi-source data to resolve inconsistency across pharmacogenomic datasets in drug sensitivity prediction.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2026

Same author

Alcohol use disorder-associated gene FNDC4 alters glutamatergic and GABAergic neurogenesis in neural organoids.

The Journal of clinical investigation·2026

Same author

USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer.

Nature communications·2025

Same author

Quantifying Sample Representation in Global Pharmacogenomic Studies of Major Depressive Disorder: A Systematic Review.

Clinical and translational science·2025

Same author

Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop.

The Journal of clinical investigation·2025

Same journal

Tools for computational analysis of moving boundary problems in cellular mechanobiology.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Cellular reprogramming: Mathematics meets medicine.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Thermoregulation: A journey from physiology to computational models and the intensive care unit.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Mammalian cell and tissue imaging using Raman and coherent Raman microscopy.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Regulating cellular cyclic adenosine monophosphate: "Sources," "sinks," and now, "tunable valves".

Wiley interdisciplinary reviews. Systems biology and medicine·2020

Same journal

Molecular networks in Network Medicine: Development and applications.

Wiley interdisciplinary reviews. Systems biology and medicine·2020

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Pharmacogenomics: a systems approach.

Liewei Wang¹

¹Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.

Wiley Interdisciplinary Reviews. Systems Biology and Medicine

|September 14, 2010

Summary

This summary is machine-generated.

Pharmacogenetics and pharmacogenomics study how genes affect drug response, advancing individualized medicine. This field integrates genomics, transcriptomics, and metabolomics for better drug development and clinical application.

More Related Videos

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins

Published on: June 11, 2015

Related Experiment Videos

Last Updated: Jun 8, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins

Published on: June 11, 2015

Area of Science:

Pharmacogenetics and Pharmacogenomics
Genomics
Systems Biology

Background:

Inheritance significantly influences individual drug response, leading to adverse reactions or lack of efficacy.
Pharmacogenetics initially focused on monogenic traits and drug metabolism variations.
The field is evolving into pharmacogenomics, incorporating broader genomic and systems-based approaches.

Purpose of the Study:

To provide an overview of the evolution of pharmacogenetics and pharmacogenomics.
To highlight scientific advances driving the discipline's progress.
To discuss the integration of transcriptomic and metabolomic data for predicting drug response.

Main Methods:

Review of historical and contemporary pharmacogenetic and pharmacogenomic studies.
Analysis of the integration of pharmacokinetic (PK) and pharmacodynamic (PD) pathways.
Examination of genome-wide, transcriptomic, and metabolomic approaches.

Main Results:

Pharmacogenetics has evolved into pharmacogenomics, a systems-based discipline.
Advances in genomics have facilitated a deeper understanding of drug response variations.
The field is expanding to include pharmacotranscriptomics and pharmacometabolomics.

Conclusions:

Pharmacogenomics is a key component of individualized medicine.
Integrating multi-omics data enhances the prediction of drug response phenotypes.
Translating pharmacogenomic findings into clinical practice and drug development remains a critical challenge.